| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | INCB57643 | |
| 3 | Generic | ||
| 4 | Indication | Myelofibrosis | |
| 5 | MOA | BET inhibitor | |
| 6 | Clinical Trials | ||
| 7 | Phase II myelofibrosis with ruxolitinib |
| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | INCB57643 | |
| 3 | Generic | ||
| 4 | Indication | Myelofibrosis | |
| 5 | MOA | BET inhibitor | |
| 6 | Clinical Trials | ||
| 7 | Phase II myelofibrosis with ruxolitinib |
Martin Shkreli